GlassScriptPhysician profile
Jasen Cheng Chi
NPI 1437141322
$29,981.14
in general payments reported to CMS, 2019-2025
37 companies · $4,461 in 2025
The $4,461 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,634 · 2020: $3,139 · 2021: $4,222 · 2022: $4,525 · 2023: $3,995 · 2024: $4,005 · 2025: $4,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,400.75 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,164.11 | 2019-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $5,024.67 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $3,459.76 | 2019-2025 | Simponi Aria, Tremfya, Simponi |
| Ucb, INC. | $3,334.25 | 2019-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $2,129.56 | 2021-2025 | Saphnelo, Evusheld |
| Glaxosmithkline, LLC. | $1,103.90 | 2019-2025 | Benlysta |
| Pfizer INC. | $1,048.51 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $921.09 | 2019-2025 | |
| Genentech USA, INC. | $814.35 | 2020-2025 | Actemra |
| Organon LLC | $757.77 | 2021-2025 | Renflexis, Hadlima, Nexplanon |
| Lilly USA, LLC | $725.22 | 2019-2025 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $702.84 | 2020-2025 | Ofev, Cyltezo |
| Mallinckrodt Hospital Products INC. | $670.97 | 2020-2025 | Acthar |
| Fresenius Kabi USA, LLC | $515.05 | 2023-2025 | Idacio, Tyenne |
| E.R. Squibb & Sons, L.L.C. | $461.34 | 2020-2025 | Orencia |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $364.56 | 2019-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $332.86 | 2021-2024 | Lupkynis |
| Celgene Corporation | $156.74 | 2019 | |
| Merck Sharp & Dohme LLC | $156.67 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $142.59 | 2019-2022 | |
| Genzyme Corporation | $139.35 | 2019-2021 | |
| Horizon Therapeutics Plc | $126.16 | 2020-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $102.96 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $94.93 | 2019-2023 | Mitigare |
| Zyla Life Sciences, INC. | $74.92 | 2019-2020 | |
| Kyowa Kirin, INC. | $73.67 | 2024 | Crysvita |
| Ani Pharmaceuticals, INC. | $71.24 | 2022-2024 | Purified Cortrophin Gel |
| Scilex Pharmaceuticals INC. | $65.81 | 2024 | |
| Pacira Therapeutics, INC. | $44.96 | 2019 | |
| Lundbeck LLC | $42.98 | 2022-2024 | Vyepti |
| Jazz Pharmaceuticals INC. | $33.27 | 2021 | |
| Bioventus LLC | $32.26 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $25.04 | 2019 | |
| Mallinckrodt Enterprises LLC | $23.82 | 2019 | |
| Gilead Sciences, INC. | $18.31 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.73 | 2021 | |
| Sebela Pharmaceuticals INC. | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasen Chi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.